Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NKTRthis companyNektar Therapeutics	$37.56	-4.35×	7.94×	12.91×	-6.18×	-172.6%	100.0%	-236.8%	-297.1%	-182.6%	-52.8%	-29.3%	1.66×	-0.98×	-4.99×	4.97×	0.0%	1	-1.18	2	C
CHRSCoherus Oncology, Inc.	$0.81	-0.98×	2.8×	4.05×	-0.72×	-124.2%	57.9%	-425.7%	-403.8%	-279.1%	-151.8%	-81.0%	0.66×	0.29×	-19.95×	1.46×	0.0%	2	-12.02	1	C-
CRVSCorvus Pharmaceuticals, Inc.	$11.10	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
MGNXMacroGenics, Inc.	$2.44	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
RCUSArcus Biosciences, Inc.	$18.75	-7.24×	4.06×	10.36×	-7.31×	-306.1%	96.0%	-156.3%	-142.9%	-55.9%	-41.9%	-18.9%	0.18×	0.33×	-48.25×	4.36×	0.0%	0	-0.28	1	D+
XNCRXencor, Inc.	$38.36	-12.35×	1.79×	9.05×	-27.04×	-122.2%	91.6%	-141.4%	-73.2%	-14.5%	-21.5%	-12.2%	0.3×	-2.85×	-5.56×	6.25×	0.0%	2	4.41	2	C
Peer median	—	-7.24×	2.8×	4.05×	-7.31×	-124.2%	71.1%	-141.4%	-73.2%	-55.9%	-41.9%	-18.9%	0.3×	0.24×	-8.56×	5.1×	0.0%	2	-0.28	1	—